SuperworthBiogen profit margin BIIB
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 8.3%
- Operating margin, 12 months
- 12.3%
- Net margin on a year earlier
- −7.0 pts
- Peer median
- 6.7%
Over the twelve months to Jun 30, 2026, Biogen kept 8.3% of its revenue as net profit, with an operating margin of 12.3% and a gross margin of 74.0%.
Five years earlier its net margin was 16.4%.
The median for 10 large drugmakers of a similar size is 6.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 13.1% | 18.8% | 75.7% |
| FY2024 | 16.9% | 23.2% | 76.1% |
| FY2023 | 11.8% | 16.4% | 74.2% |
| FY2022 | 29.9% | 29.3% | 77.6% |
| FY2021 | 14.2% | 25.9% | 80.8% |
| FY2020 | 29.8% | 33.8% | 86.6% |
| FY2019 | 41.0% | 49.0% | 86.4% |
| FY2018 | 32.9% | 43.8% | 86.5% |
| FY2017 | 20.7% | 43.6% | 86.7% |
| FY2016 | 32.3% | 45.0% | 87.1% |
| FY2015 | 33.0% | 45.4% | 88.5% |
| FY2014 | 30.2% | 40.9% | 87.9% |
| FY2013 | 26.9% | 36.3% | 87.6% |
| FY2012 | 25.0% | 33.6% | 90.1% |
| FY2011 | 24.5% | 34.2% | 90.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 8.3% | −7.0 pts | 12.3% | |
| Q1 FY26 | 13.8% | −1.3 pts | 18.9% | |
| Q4 FY25 | 13.1% | −3.8 pts | 18.8% | |
| Q3 FY25 | 16.0% | −0.8 pts | 21.9% | |
| Q2 FY25 | 15.3% | +3.3 pts | 20.8% | |
| Q1 FY25 | 15.1% | +3.0 pts | 21.1% | |
| Q4 FY24 | 16.9% | +5.1 pts | 23.2% | |
| Q3 FY24 | 16.8% | +2.2 pts | 22.6% | |
| Q2 FY24 | 12.0% | −14.7 pts | 19.2% | |
| Q1 FY24 | 12.1% | −18.9 pts | 17.2% | |
| Q4 FY23 | 11.8% | −18.1 pts | 16.4% | |
| Q3 FY23 | 14.6% | −13.0 pts | 19.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.
| Company | Profit margin |
|---|---|
| BIIBBiogen | 8.3% |
| JAZZJazz Pharmaceuticals | 20.4% |
| BMYBristol-Myers Squibb | 18.9% |
| BMRNBiomarin Pharmaceutical | 2.1% |
| CORTCorcept Therapeutics | 6.6% |
| PTGXProtagonist Therapeutics | 29.4% |
| TGTXTG Therapeutics | 55.2% |
| PFEPfizer | 6.8% |
| ALKSAlkermes plc. | 4.0% |
| GILDGilead Sciences | −10.6% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| Peer median | 6.7% |
Where Biogen ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Biogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.